1. AI is generating value, but spending is a concern
Executives at large technology companies emphasised during their earnings calls how investments in artificial intelligence have already contributed to business growth. These statements may have been made to address investor concerns about increased capital expenditure to support AI.
“Every AI-driven company seems to have a good story about how AI is showing some positive impact to revenue, which is one reason their stocks aren’t too far off from their all-time highs,” Casey says.
Meta CEO Mark Zuckerberg noted that “advances in AI continue to improve the quality of recommendations and drive engagement.” One of the company’s long-term goals is to provide marketers the ability to automate the processes of creating and testing advertising content.
Still, investors are nervous about increased spending. “In some cases, the check sizes are getting so large it’s hard to imagine the investment return can be there,” Casey says.
If a recession hits, lower spending from customers could crimp profits, but the impacts to long-term stock prices are harder to predict.
“My simplifying approach to investing is to think four to eight years out and assume there is a recession between now and then. Then I try to determine which companies are likely to be larger and more profitable at that point in the future than their stock prices currently assume,” Casey says. The exercise helps him work through near-term volatility and avoid rash decisions.
2. Companies with weight loss drugs widen their lead
The duopoly for weight loss and diabetes drugs from Eli Lilly and Novo Nordisk is likely to continue for some time, says equity analyst Christopher Lee, who covers US pharmaceuticals and biotechnology companies.
Eli Lilly, which sells Mounjaro and Zepbound, aggressively invested in manufacturing capacity as high demand landed those products on the Food and Drug Administration’s shortage list. In early August, the government’s database indicated they are now available.
“Competitors are coming around to the idea that they need to have a product that differs from or is complementary to obesity drugs currently on the market,” Lee says. For example, some companies are working on drugs that will preserve muscle mass as people lose weight.
The moat has widened because Eli Lilly and Novo Nordisk, maker of Ozempic and Wegovy, have invested billions into their franchises over the past 20 years. “By the time a competitor has a product, Eli Lilly and Novo Nordisk will have built a strong wall with commercial insurers. Often referred to as a rebate wall, the practice makes it difficult for competitors to gain traction for their drugs,” Lee notes.
Meanwhile, investors concerned about a slowdown in the economy could take the opportunity to review their health care exposure overall, Lee adds. The sector has tended to hold up well compared to the S&P 500 in a downturn as opting out of life-saving medication is usually not a choice for most consumers.